GDRX — GoodRx Holdings, Inc. stock price, charts and financials

NASDAQ·Healthcare·Medical - Healthcare Information Services·USA

Latest market price

3.34

+0.18+5.70%

Overview Short InterestFilings

GDRXQT51GoodRx Holdings, Inc.·NASDAQ

Overview Short InterestFilings

3.34+5.70%

Earnings

Up 5.7% — Reported earnings — EPS missed by 3%, revenue beat by 5%.

High confidence

Loading chart...

Screen all →

TDOC+0.45%$6.71 OMDA-1.61%$20.18 CERT-4.65%$7.80 HSTM+5.19%$29.80 PHR+1.24%$11.44 WGS+4.48%$70.90 HTFL+1.94%$27.28 PGNY-0.16%$31.48

Snapshot

Index	-	P/E	52.67	EPS (ttm)	0.06	Insider Own	43.01%	Shs Outstand	346.63M	Perf Week	3.61%

Market Cap	1.10B	Forward P/E	8.85	EPS next Y	0.36	Insider Trans	0.00%	Shs Float	285.46M	Perf Month	3.61%

Enterprise Value	1.40B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	2.26%	Perf Quarter	23.92%

Income	20.00M	P/S	1.39	EPS this Y	415.07%	Inst Trans	-	Short Ratio	4.36	Perf Half Y	39.21%

Sales	788.00M	P/B	1.76	EPS next Y	15.49%	ROA	1.02%	Short Interest	6.46M	Perf YTD	16.61%

Book/sh	1.79	P/C	4.64	EPS next 5Y	-	ROE	3.31%	52W High	6.14 -45.61%	Perf Year	-34.03%

Cash/sh	0.68	P/FCF	11.02	EPS past 3/5Y	-	ROIC	3.26%	52W Low	1.87 78.53%	Perf 3Y	-52.41%

Dividend Est.	-	EV/EBITDA	8.07	Sales past 3/5Y	1.29% 7.66%	Gross Margin	86.56%	Volatility	4.84% 4.18%	Perf 5Y	-89.85%

Dividend TTM	-	EV/Sales	1.77	EPS Y/Y TTM	43.54%	Oper. Margin	10.73%	ATR (14)	0.14	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	1.47	Sales Y/Y TTM	-0.51%	Profit Margin	2.61%	RSI (14)	58.68	Recom	2.63

Dividend Gr. 3/5Y	-	Current Ratio	1.47	EPS Q/Q	-22.22%	SMA20	3.67%	Beta	1.56	Target Price	3.25

Payout	0.00%	Debt/Eq	0.87	Sales Q/Q	-4.43%	SMA50	9.49%	Rel Volume	0.55	Prev Close	3.16

Employees	697	LT Debt/Eq	0.87	Earnings	Aug 05	SMA200	17.84%	Avg Volume	1.40M	Price	3.34

IPO Date	Sep 23, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.66% 4.64%	Net Debt/EBITDA	1.76	Volume	769,678	Change	5.70%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-08-26	Reiterated	Goldman Sachs	Neutral	$2.50 → $3.50
Feb-27-26	Downgrade	JP Morgan	Overweight → Neutral
Feb-26-26	Reiterated	Leerink Partners		$3.00
Jan-22-26	Downgrade	Jefferies	Buy → Hold	$2.75
Dec-18-25	Reiterated	Morgan Stanley	Equal Weight	$9.50 → $4.00
Dec-08-25	Initiated	Barclays	Underweight	$9.00 → $3.00
Aug-11-25	Reiterated	Deutsche Bank	Hold	$8.00 → $6.00
Jun-10-24	Reiterated	Morgan Stanley	Equal Weight	$9.50
May-23-24	Upgrade	RBC Capital	Sector Perform → Outperform	$10
May-16-24	Upgrade	Raymond James	Market Perform → Outperform	$10

Latest News

Jul-12-26

Jul-12-2605:07AM

GoodRx Holdings (GDRX) Pharma Growth Story Meets A Small Fair Value GapYahoo

Jul-09-26

Jul-09-2604:05PM

GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Callbusinesswire.com

Jul-08-26

Jul-08-2601:01PM

GoodRx (GDRX) Upgraded to Buy: What Does It Mean for the Stock?zacks.com

12:41PM

GDRX or HQY: Which Is the Better Value Stock Right Now?zacks.com

10:41AM

Is GoodRx (GDRX) Stock Undervalued Right Now?zacks.com

Jun-25-26

Jun-25-2608:30PM

[Latest] Global Healthcare Discount Plan Market Size/Share Worth USD 48.37 Billion by 2035 at a 8.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)Yahoo

09:13AM

2 Healthcare Stocks to Consider Right Now and 1 We Brush OffYahoo

Company

GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering customized, geographically tailored prescription pricing. It also grants access to special, negotiated rates through unique GoodRx codes, which can be utilized for savings on prescriptions throughout the entire United States. Beyond this core offering, the firm also extends its portfolio to include subscription services, programs designed for pharmaceutical manufacturers, and telehealth capabilities. GoodRx additionally collaborates with pharmacy benefit managers, entities responsible for managing drug formularies and overseeing prescription transactions, including the critical task of setting prices between consumers and pharmacies. The company was founded in 2015 and maintains its principal office in Santa Monica, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	788	797	792	750	767	745	551	388	250
Cost of Goods Sold Incl. D&A	105	58	48	67	65	47	30	14	6
Gross Profit	682	739	744	683	701	699	521	374	243
Selling, General and Administrative Excl. Other	440	446	485	467	502	525	717	192	113
Research and Development	120	121	124	136	143	126	62	29	44
Other Operating Expense	38	85	69	107	55	34	18	14	9
Operating Income	86	87	66	-27	2	13	-276	140	77
Interest Expense	42	43	53	57	34	24	28	50	22
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	3	12	19	28	9	0	0	-7	-3
Net Income Before Taxes	46	57	31	-56	-23	-10	-303	83	52
Income Taxes	25	26	15	-47	10	15	-10	17	9
Consolidated Net Income	20	30	16	-9	-33	-25	-294	66	44
Net Income From Continuing Operations	20	30	16	-9	-33	-25	-294	66	44
Net Income	20	30	16	-9	-33	-25	-294	66	44
EPS (Recurring)	0.06	0.09	0.04	-0.02	-0.08	-0.06	-1.07	0.12	0.12
EPS (Basic, Before Extraordinaries)	0.06	0.09	0.04	-0.02	-0.08	-0.06	-1.07	0.12	0.12
EPS (Diluted)	0.06	0.09	0.04	-0.02	-0.08	-0.06	-1.07	0.12	0.12
EBITDA	173	184	154	109	65	48	-257	146	84
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	55.67	31.77	111.24	—	—	—	—	—	—
Price To Sales Ratio	1.45	1.21	2.27	3.66	2.51	17.98	20.13	—	—
Gross Margin	86.55	92.72	93.94	91.07	91.40	93.83	94.56	96.39	97.20
Operating Margin	10.91	10.92	8.33	-3.60	0.26	1.74	-50.09	36.08	30.80
Net Margin	2.54	3.76	2.02	-1.20	-4.30	-3.36	-53.36	17.01	17.60
Shares Outstanding	341	356	386	410	413	410	275	356	356
Market Capitalization	1,139	965	1,795	2,747	1,925	13,399	11,094	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McGinnis Christopher A	See Remarks	Jul 15 '26	Option Exercise	0.00	36,988	0	214,604	Jul 16
Barnes Wendy Lynn	See Remarks	Jul 15 '26	Option Exercise	0.00	277,288	0	789,860	Jul 16
Chan Thomas (TC)	Chief Accounting Officer	Jul 15 '26	Option Exercise	0.00	5,792	0	11,527	Jul 16
Chan Thomas (TC)	Chief Accounting Officer	Jun 15 '26	Option Exercise	0.00	4,069	0	6,804	Jun 15
Chan Thomas (TC)	Chief Accounting Officer	May 15 '26	Option Exercise	0.00	5,575	0	4,595	May 15
McGinnis Christopher A	See Remarks	May 15 '26	Option Exercise	0.00	44,779	0	197,342	May 15
McGinnis Christopher A	See Remarks	Apr 15 '26	Option Exercise	0.00	36,987	0	406,865	Apr 15
Barnes Wendy Lynn	See Remarks	Apr 15 '26	Option Exercise	0.00	277,288	0	633,028	Apr 15
REY-GIRAUD AGNES	Director	Mar 12 '26	Option Exercise	0.47	192,185	90,327	277,633	Mar 13
Nabiey Romin	Chief Accounting Officer	Mar 08 '26	Option Exercise	0.00	12,434	0	185,949	Mar 09
Nabiey Romin	Chief Accounting Officer	Feb 15 '26	Option Exercise	0.00	4,804	0	177,727	Feb 17
McGinnis Christopher A	See Remarks	Feb 15 '26	Option Exercise	0.00	179,120	0	179,120	Feb 17
Nabiey Romin	Chief Accounting Officer	Feb 08 '26	Option Exercise	0.00	12,663	0	178,138	Feb 09
Wagner Scott	Director	Jan 21 '26	Option Exercise	0.00	31,394	0	216,663	Jan 21
Barnes Wendy Lynn	See Remarks	Jan 15 '26	Option Exercise	0.00	665,302	0	516,919	Jan 15

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.